Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) Research & Development (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Research & Development data on record, last reported at $167000.0 in Q3 2025.

  • For Q3 2025, Research & Development fell 2.91% year-over-year to $167000.0; the TTM value through Sep 2025 reached $576000.0, down 31.35%, while the annual FY2024 figure was $813000.0, 45.18% up from the prior year.
  • Research & Development reached $167000.0 in Q3 2025 per UTMD's latest filing, up from $135000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $266000.0 in Q1 2024 and bottomed at $112000.0 in Q3 2022.
  • Average Research & Development over 5 years is $149947.4, with a median of $135000.0 recorded in 2022.
  • Peak YoY movement for Research & Development: surged 91.73% in 2024, then plummeted 47.06% in 2025.
  • A 5-year view of Research & Development shows it stood at $141000.0 in 2021, then decreased by 12.77% to $123000.0 in 2022, then increased by 18.7% to $146000.0 in 2023, then fell by 17.81% to $120000.0 in 2024, then skyrocketed by 39.17% to $167000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $167000.0 in Q3 2025, $135000.0 in Q2 2025, and $154000.0 in Q1 2025.